Author Correction: The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans

Benjamin A H Smith¹, Carolyn R Bertozzi^{2

3

4}

Affiliations

¹ Department of Chemical & Systems Biology and ChEM-H, Stanford School of Medicine, Stanford, CA, USA.
² Department of Chemical & Systems Biology and ChEM-H, Stanford School of Medicine, Stanford, CA, USA. bertozzi@stanford.edu.
³ Department of Chemistry, Stanford University, Stanford, CA, USA. bertozzi@stanford.edu.
⁴ Howard Hughes Medical Institute, Stanford University, Stanford, CA, USA. bertozzi@stanford.edu.

Published Erratum

Benjamin A H Smith et al. Nat Rev Drug Discov. 2021 Mar.

. 2021 Mar;20(3):244.

doi: 10.1038/s41573-021-00160-1.

Benjamin A H Smith¹, Carolyn R Bertozzi^{2

3

4}

¹ Department of Chemical & Systems Biology and ChEM-H, Stanford School of Medicine, Stanford, CA, USA.
² Department of Chemical & Systems Biology and ChEM-H, Stanford School of Medicine, Stanford, CA, USA. bertozzi@stanford.edu.
³ Department of Chemistry, Stanford University, Stanford, CA, USA. bertozzi@stanford.edu.
⁴ Howard Hughes Medical Institute, Stanford University, Stanford, CA, USA. bertozzi@stanford.edu.

No abstract available

Erratum for

The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans.
Smith BAH, Bertozzi CR. Smith BAH, et al. Nat Rev Drug Discov. 2021 Mar;20(3):217-243. doi: 10.1038/s41573-020-00093-1. Epub 2021 Jan 18. Nat Rev Drug Discov. 2021. PMID: 33462432 Free PMC article. Review.